Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
L611619-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $240.90 | |
L611619-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $930.90 |
Synonyms | CFI-402257|1610759-22-2|luvixasertib|HE97PTK3Q6|CFI402257|N-cyclopropyl-4-[7-[(3-hydroxy-3-methylcyclobutyl)methylamino]-5-pyridin-3-yloxypyrazolo[1,5-a]pyrimidin-3-yl]-2-methylbenzamide|UNII-HE97PTK3Q6|CID 118086034|CHEMBL4442392|CHEMBL4469414|CFI 402257 |
---|---|
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of TTK protein kinase |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | N-cyclopropyl-4-[7-[(3-hydroxy-3-methylcyclobutyl)methylamino]-5-pyridin-3-yloxypyrazolo[1,5-a]pyrimidin-3-yl]-2-methylbenzamide |
---|---|
INCHI | InChI=1S/C28H30N6O3/c1-17-10-19(5-8-22(17)27(35)32-20-6-7-20)23-16-31-34-24(30-14-18-12-28(2,36)13-18)11-25(33-26(23)34)37-21-4-3-9-29-15-21/h3-5,8-11,15-16,18,20,30,36H,6-7,12-14H2,1-2H3,(H,32,35) |
InChi Key | PMQUGSPFUBGJCZ-UHFFFAOYSA-N |
Canonical SMILES | Cc1c(ccc(c1)c1c2nc(cc(n2nc1)NCC1CC(C1)(C)O)Oc1cnccc1)C(=O)NC1CC1 |
Isomeric SMILES | CC1=C(C=CC(=C1)C2=C3N=C(C=C(N3N=C2)NCC4CC(C4)(C)O)OC5=CN=CC=C5)C(=O)NC6CC6 |
PubChem CID | 118086034 |
PubChem CID | 118086034 |
---|---|
CAS Registry No. | 1610759-22-2 |
BindingDB Ligand | 50512456 |
Enter Lot Number to search for COA:
1. Liu Y, Laufer R, Patel NK, Ng G, Sampson PB, Li SW, Lang Y, Feher M, Brokx R, Beletskaya I et al.. (2016) Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent.. ACS Med Chem Lett, 7 (7): (671-5). [PMID:27437075] |
2. Mason JM, Wei X, Fletcher GC, Kiarash R, Brokx R, Hodgson R, Beletskaya I, Bray MR, Mak TW. (2017) Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.. Proc Natl Acad Sci U S A, 114 (12): (3127-3132). [PMID:28270606] |